Evidence mapPaperPMID 22554256Full record

ArticleAlimentary pharmacology & therapeutics2012

Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.

Z Permutt, T-A Le, M R Peterson, E Seki, D A Brenner, C Sirlin, R Loomba

5 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 184 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 5 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03590626 nacompletedstarted 2019, after this paper: background citation

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Ran2019Enrolled60Registered outcomes7Posted comparisons0ConditionsNon Alcoholic Fatty Liver Disease, Type2 Diabetes MellitusArmsDulaglutide
Open the trial in the graph
NCT05042505 nacompletedstarted 2022, after this paper: background citation

Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial

Ran2022Enrolled100Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Liver Transplant; ComplicationsArmsDapagliflozin 10mg Tab, Sitagliptin 100mg
Open the trial in the graph
NCT06060392 narecruitingstarted 2023, after this paper: background citation

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-Lit

Ran2023Enrolled50Registered outcomes17Posted comparisons0ConditionsDiabete Mellitus, Liver Transplant; ComplicationsArmsSemaglutide Pill
Open the trial in the graph
NCT03850314 phase2 / phase3unknown statusnot on this mapstarted 2019, after this paper: background citation

The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters: A Clinical and Ex-vivo Study.

TypeinterventionalSponsorProf. Tony hayek MDRan2019 to 2020Enrolled50ConditionsMetabolic Syndrome, Dyslipidemias, Diabetes Mellitus, ObesityArmsGlycine
NCT06035874 narecruitingnot on this mapstarted 2023, after this paper: background citation

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial

TypeinterventionalSponsorMedanta, The Medicity, IndiaRan2023 to 2025Enrolled100ConditionsType 2 Diabetes, Non Alcholic Fatty Liver DiseaseArmsBempedoic acid
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 5 syntheses or guidelines pooled it, 334 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Z PermuttDivision of Internal Medicine, Department of Medicine, University of California, San Diego, USA.
T-A Le
M R Peterson
E Seki
D A Brenner
C Sirlin
R Loomba
University of California, San Diego · US

Funding

GASTROENTEROLOGY TRAINING GRANTT32DK007202 · UNIVERSITY OF CALIFORNIA SAN DIEGO · 1985 to 2005
$1.5M
TNF ALPHA AND IMPAIRED WOUND HEALING OF CACHEXIA XIAR01GM041804 · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · 1989 to 2005
$1.4M
NIAAA NIH HHS R01 AA020172NIDDK NIH HHS 1K23DK090303NIDDK NIH HHS K23 DK090303NIDDK NIH HHS T32 DK007202NIGMS NIH HHS R01 GM041804
6 · The paper itself

Abstract

backgroundConventional magnetic resonance imaging (MRI) techniques that measure hepatic steatosis are limited by T1 bias, T(2)* decay and multi-frequency signal-interference effects of protons in fat. Newer MR techniques such as the proton density-fat fraction (PDFF) that correct for these factors have not been specifically compared to liver biopsy in adult patients with non-alcoholic fatty liver disease (NAFLD).

aimTo examine the association between MRI-determined PDFF and histology-determined steatosis grade, and their association with fibrosis.

methodsA total of 51 adult patients with biopsy-confirmed NAFLD underwent metabolic-biochemical profiling, MRI-determined PDFF measurement of hepatic steatosis and liver biopsy assessment according to NASH-CRN histological scoring system.

resultsThe average MRI-determined PDFF increased significantly with increasing histology-determined steatosis grade: 8.9% at grade-1, 16.3% at grade-2, and 25.0% at grade-3 with P ≤ 0.0001 (correlation: r(2) = 0.56, P < 0.0001). Patients with stage-4 fibrosis, when compared with patients with stage 0-3 fibrosis, had significantly lower hepatic steatosis by both MRI-determined PDFF (7.6% vs. 17.8%, P < 0.005) and histology-determined steatosis grade (1.4 vs. 2.2, P < 0.05). NAFLD patients with grade 1 steatosis were more likely to have characteristics of advanced liver disease including higher average AST:ALT (0.87 vs. 0.60, P < 0.02), GGT (140 vs. 67, P < 0.01), and INR (1.06 vs. 0.99, P < 0.01), higher stage of fibrosis and hepatocellular ballooning.

conclusionsMRI-determined proton density-fat fraction correlates with histology-determined steatosis grade in adults with NAFLD. Steatosis is non-linearly related to fibrosis progression. In patients with NAFLD, a low amount of hepatic steatosis on imaging does not necessarily indicate mild disease.

Indexed as

Magnetic Resonance ImagingAdultBiopsyCohort StudiesCross-Sectional StudiesFatty LiverFemaleHumansLiverLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePredictive Value of TestsProspective StudiesSeverity of Illness Index

Identifiers

PMID22554256
PMCPMC3437221
OpenAlexW1983496515

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.